Study Title

Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)

Study Details

Description:

This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).

Sponsor:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Contacts:

Margaret McJannett

trials@anzup.org.au

+61295625033

Izabella Pokorski

evolution.study@sydney.edu.au

+61295625000

Government Study Link:

NCT05150236 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468